1. Home
  2. |Insights
  3. |Federal Trade Commission Votes to Conduct Study on Patent Assertion Entities

Federal Trade Commission Votes to Conduct Study on Patent Assertion Entities

Client Alert | 2 min read | 09.27.13

The FTC announced on September 27 that after a unanimous vote, the Commissioners have decided to launch a study of patent assertion entities (PAEs) and their effect on innovation and competition. The agency has long indicated interest in this issue. The study, which will be conducted pursuant to Section 6(b) of the FTC Act, will allow the FTC to issue compulsory process orders to gather information from PAEs, as well as from other companies that operate in the wireless communications sector.

PAEs have lately garnered scrutiny from the Obama Administration, Congress, and private litigants, as described in more depth here. Their effect on competition and innovation is, however, difficult to measure, because details about licensing transactions are often confidential. But the Commission has the authority to collect non-public information, such as licensing agreements and cost and revenue data. As a result, the study is expected to generate a much richer set of data from which the Commission will be able to draw conclusions. According to the Commission's announcement, the study will target specific issues, including (1) the corporate structure of PAEs; (2) the type of patents held by PAEs; (3) the licensing and litigation conduct of PAEs; and (4) the operating costs and revenues of PAEs.

While the Commission has emphasized on various occasions that it has not yet drawn any conclusions about whether PAEs have a negative effect on competition and innovation, a 6(b) study has the potential to result in enforcement actions in the future. For example, the Commission's position against reverse payment settlements in the pharmaceutical industry was solidified after it conducted a 6(b) study on that subject from 2000 through 2002.

The FTC has issued a public call for comments on proposed information requests to PAEs, and it will accept such comments for 60 days, at this address. Upon expiration of the comment period, the FTC will seek clearance from the Office of Management and Budget to commence issuing compulsory process orders.

Contacts

Insights

Client Alert | 5 min read | 12.12.25

Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality

On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument....

View All Insights